Roche: positive opinion from CHMP on Tecentriq
(CercleFinance.com) - Roche has announced that the CHMP of the European Medicines Agency has recommended the approval of its Tecentriq, in combination with Avastin, for the treatment of adults with advanced or unresectable hepatocellular carcinomas.
Based on this recommendation, a final decision on the approval of Tecentriq in this combination and for this disease, with full details of the approved indication, is expected from the European Commission in the near future.
Copyright (c) 2020 CercleFinance.com. All rights reserved.